Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus Identifier:
First received: March 22, 2010
Last updated: May 9, 2016
Last verified: May 2016